Invesaro

Stocks Health care AUTL

NASDAQ · Health care

Autolus Therapeutics plc (AUTL)

Autolus Therapeutics plc brought in $117.4M of revenue over the twelve months to June 30, 2026, up 292.2% from a year earlier. It posted a net loss of $280.2M. In fiscal 2025 capital spending exceeded operating cash flow by $302.6M. At June 30, 2026 it held $171.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

Price
$1.86
-2.88% on the day · September 25, 2026
52-week range $1.18 to $2.58
Market cap
$493.7M
Revenue (last 12 months)
$117.4M
+292.2% year on year
Net margin
-238.7%

What Autolus Therapeutics plc does

Autolus Therapeutics plc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker AUTL.

Revenue and profit by year

Revenue
FY18: $1.4M $1.4M FY18FY19: $2.9M $2.9M FY19FY23: $1.7M $1.7M FY23FY24: $10.1M $10.1M FY24FY25: $75.4M $75.4M FY25
Net income
FY18: -$44.8M -$44.8M FY18FY19: -$123.8M -$123.8M FY19FY20: -$142.1M -$142.1M FY20FY21: -$142.1M -$142.1M FY21FY22: -$148.8M -$148.8M FY22FY23: -$208.4M -$208.4M FY23FY24: -$220.7M -$220.7M FY24FY25: -$287.5M -$287.5M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$75.4M-$270.5M-$287.5M-$1.08-$302.6M
2024$10.1M-$241.4M-$220.7M-$0.86-$228.3M
2023$1.7M-$179.7M-$208.4M-$1.20-$156.6M
2022n/a-$143.4M-$148.8M-$1.57-$123.1M
2021n/a-$141.1M-$142.1M-$1.97-$126.7M
2020n/a-$168.1M-$142.1M-$2.76-$132.4M

Latest SEC filings

What Autolus Therapeutics plc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 22, 2026
  2. September 15, 2026
  3. September 14, 2026
  4. August 28, 2026
  5. August 14, 2026
  6. August 11, 2026
    Quarterly report 10-Q · period to June 30, 2026
  7. August 11, 2026
  8. August 3, 2026
  9. August 3, 2026
  10. June 29, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 3, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about AUTL

What does Autolus Therapeutics plc do?

Autolus Therapeutics plc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker AUTL.

Is Autolus Therapeutics plc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $280.2M on revenue of $117.4M.

How much revenue does Autolus Therapeutics plc make?

Over the twelve months to June 30, 2026 Autolus Therapeutics plc reported revenue of $117.4M. That is 292.2% more than a year earlier.

When did Autolus Therapeutics plc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the securities offering prospectus from September 22, 2026.

Similar companies

Follow AUTL

Get an email when Autolus Therapeutics plc files with the SEC: results, executive changes, material agreements and annual reports.

Follow AUTL: get an email when it files

Where the numbers come from

Financial figures are the values Autolus Therapeutics plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.